International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2013
NCT02051868
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now